ALS on the Cusp
This article was originally published in Start Up
Executive Summary
Amyotrophic lateral sclerosis, the devastating neurodegenerative disease, has largely defied R&D efforts, but emerging knowledge, much of it through nonprofit research organizations, raises hopes for better results and treatments with blockbuster potential. In this issue we profile two emerging drug developers hoping to make an impact: Cambria Pharmaceuticals and Knopp Neurosciences.
You may also be interested in...
Scientific Advances Increase Potential For Drugs To Treat ALS
New understanding of the spectrum of CNS disorders and rising interest from biotechs have revealed new targets, new biomarkers and new opportunities to treat the fast-acting and deadly neurodegenerative disease. Add to that an open stakeholder forum hosted by FDA Feb. 25 that could clarify regulatory and clinical expectations, and the tide may be turning on amyotrophic lateral sclerosis.
FDA Finds Statins Not Linked To ALS; When Can A False Alarm Be Turned Off?
FDA's determination that statins do not increase the incidence of amyotrophic lateral sclerosis suggests that agency will continue to rely on data from placebo controlled trials to address concerns raised in post-marketing reports
Start-Up Previews (07/2008)
A preview of the emerging health care companies profiled in the current, all-profiles issue of Start-Up. This month's profile groups are "Glioblastoma Start-Ups Get Specific," "Glaucoma Start-Ups Reach Critical Mass," and "ALS on the Cusp." Plus these Start-Ups Across Health Care: EarlySense, NeoChord, and Pantec Biosolutions.